Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

Abstract Background The effectiveness of ustekinumab (UST) in the treatment of Crohn’s disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naïve and anti-TNF-exposed patients. Given the selective nature of pivotal trial designs, real-world ef...

Full description

Bibliographic Details
Main Authors: Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz, Aderson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Liliana Andrade Chebli, Erika Ruback Bertges, Antonio José Tiburcio Alves Junior, Orlando Ambrogini Junior, Bianca Loyo Pona Schiavetti da Silva, Marcio Lubini, Mauro Bafutto, Cristina Flores, Eduardo Garcia Vilela, Sandra Felice Boratto, Newton Luiz Tricarico Gasparetti Junior, Flavio Steinwurz, Nayara Salgado Carvalho, Omar Féres, José Joaquim Ribeiro da Rocha
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Gastroenterology
Subjects:
Ustekinumab
Crohn’s disease
Inflammatory bowel disease
Biological therapy
Online Access:https://doi.org/10.1186/s12876-022-02280-3

Internet

https://doi.org/10.1186/s12876-022-02280-3

Similar Items